Lilly drug fails in breast cancer, succeeds in gastric cancer
Sept 26 (Reuters) - Eli Lilly and Co said its experimental cancer drug failed to improve the survival among breast cancer patients without their cancer worsening in a late-stage trial.
However, a separate trial, testing the drug as a treatment for advanced gastric cancer, met the main goal of improving patients' survival.
Lilly said it does not plan to submit an approval application for the drug, ramucirumab, for treating advanced breast cancer.
- Atheists face death in 13 countries, global discrimination: study
- Missouri executes man for killing good Samaritan motorist in 1994
- Focus turns to Thai military, anti-government protesters tell them to pick sides
- Google executives' planes saved millions in costs due to error - NASA
- Apple scores legal victory over Samsung in South Korea